An analysis of SARS-CoV-2 antibodies from participants in an mRNA-1273 (Moderna) vaccine efficacy trial has brought scientists closer to identifying a correlate of protection against COVID-19. The surrogate immunological markers are needed to accelerate the path to modified or new vaccines and to quickly expand existing vaccines into new groups.